334 related articles for article (PubMed ID: 32806791)
1. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.
Chatterjee M; van Steenoven I; Huisman E; Oosterveld L; Berendse H; van der Flier WM; Del Campo M; Lemstra AW; van de Berg WDJ; Teunissen CE
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32806791
[TBL] [Abstract][Full Text] [Related]
2. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
5. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
6. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
8. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
[TBL] [Abstract][Full Text] [Related]
9. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
11. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
[TBL] [Abstract][Full Text] [Related]
12. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
13. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
[TBL] [Abstract][Full Text] [Related]
14. Pathology-associated change in levels and localization of SIDT2 in postmortem brains of Parkinson's disease and dementia with Lewy bodies patients.
Fujiwara Y; Kabuta C; Sano T; Murayama S; Saito Y; Kabuta T
Neurochem Int; 2022 Jan; 152():105243. PubMed ID: 34800582
[TBL] [Abstract][Full Text] [Related]
15. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
16. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
17. Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies.
Kokoulina P; Rohn TT
Neurodegener Dis; 2010; 7(4):243-50. PubMed ID: 20551689
[TBL] [Abstract][Full Text] [Related]
18. HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies.
Bohush A; Niewiadomska G; Weis S; Filipek A
J Parkinsons Dis; 2019; 9(1):97-107. PubMed ID: 30741686
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
[TBL] [Abstract][Full Text] [Related]
20. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and dementia with Lewy bodies.
Frigerio I; Bouwman MMA; Noordermeer RTGMM; Podobnik E; Popovic M; Timmermans E; Rozemuller AJM; van de Berg WDJ; Jonkman LE
Acta Neuropathol Commun; 2024 Jan; 12(1):4. PubMed ID: 38173031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]